Given the fact that FGF23-mAb promoted consistent improvements in Hyp mouse dentin formation, burosumab administration might be associated with decreased dental abscesses, as recently indicated in a monocentric clinical trial.21 Abnormal dentin mineralization together with enlarged pulp chambers is considered as the main culprit for the high incidence of dental abscesses in XLH patients.33–36 The randomized phase 3 clinical trials conducted in children37 or in adults38 with XLH did not report the benefit of burosumab on the dental abscess. Here, FGF23 is linked to X-linked hypophosphatemia.